Baird Financial Group
SABS icon

Baird Financial Group’s SAB Biotherapeutics SABS Stock Holding History

Baird Financial Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000
Closed -$6.88K – 1792
2023
Q4 		$6.88K Hold
1,000
– – ﹤0.01% 1705
2023
Q3 		$6.3K Hold
1,000
– – ﹤0.01% 1705
2023
Q2 		$8.3K Hold
1,000
– – ﹤0.01% 1682
2023
Q1 		$4.4K Hold
1,000
– – ﹤0.01% 1683
2022
Q4 		$6K Buy
+1,000
New +$9.14K ﹤0.01% 1679

Other funds holding SABS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Baird Financial Group's SABS Position: Q1 2024 in Review

Baird Financial Group sold out of SAB Biotherapeutics (SABS) in Q1 2024, closing a stake of 1,000 shares — an estimated $6.88K sold.

Baird Financial Group first reported a position in SABS in Q4 2022 and held it in 5 quarters. The position peaked at $8.3K in Q2 2023. 24 funds tracked by Wall St. Rank hold SABS as of Q1 2024.

  • Baird Financial Group reported no remaining SAB Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Baird Financial Group sold 1,000 SAB Biotherapeutics shares in Q1 2024, an estimated $6.88K.
  • Baird Financial Group first reported a position in SAB Biotherapeutics in Q4 2022 and held it in 5 quarters.
  • Baird Financial Group's SAB Biotherapeutics position peaked at $8.3K in Q2 2023.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2024.

Based on Baird Financial Group's 13F filing for Q1 2024, filed 14 May 2024.